Dataset Information


Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.

ABSTRACT: BACKGROUND:Patients with human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPC) have substantially better treatment response and overall survival (OS) than patients with HPV-negative disease. Treatment options for HPV+ OPC can involve either a primary radiotherapy (RT) approach (± concomitant chemotherapy) or a primary surgical approach (± adjuvant radiation) with transoral surgery (TOS). These two treatment paradigms have different spectrums of toxicity. The goals of this study are to assess the OS of two de-escalation approaches (primary radiotherapy and primary TOS) compared to historical control, and to compare survival, toxicity and quality of life (QOL) profiles between the two approaches. METHODS:This is a multicenter phase II study randomizing one hundred and forty patients with T1-2?N0-2 HPV+ OPC in a 1:1 ratio between de-escalated primary radiotherapy (60?Gy)?±?concomitant chemotherapy and TOS?±?de-escalated adjuvant radiotherapy (50-60?Gy based on risk factors). Patients will be stratified based on smoking status (


PROVIDER: S-EPMC7023689 | BioStudies | 2020-01-01

SECONDARY ACCESSION(S): 10.15585/mmwr.mm6526a1

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6189290 | BioStudies
2018-01-01 | S-EPMC6065203 | BioStudies
2016-01-01 | S-EPMC6460758 | BioStudies
2016-01-01 | S-EPMC4754145 | BioStudies
2018-01-01 | S-EPMC6297752 | BioStudies
1000-01-01 | S-EPMC4351352 | BioStudies
2018-01-01 | S-EPMC6204434 | BioStudies
1000-01-01 | S-EPMC5674099 | BioStudies
2019-01-01 | S-EPMC6779788 | BioStudies
2014-01-01 | S-EPMC4184913 | BioStudies